Repligen (NASDAQ:RGEN) Shares Gap Down – Time to Sell?

Repligen Corporation (NASDAQ:RGEN)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $145.49, but opened at $131.95. Repligen shares last traded at $137.0930, with a volume of 451,431 shares trading hands.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen agreed to buy BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, adding BioLife’s biopreservation media and cell processing tools to Repligen’s portfolio and broadening its exposure to cell therapy. Article Title
• Positive Sentiment: Management said the deal should be accretive to revenue growth, margins, and adjusted EPS, with at least $20 million of synergies in year one and $30 million in year two, which supports the investment case for long-term earnings growth. Article Title
• Neutral Sentiment: The purchase price includes both cash and Repligen shares, so while the acquisition could create growth opportunities, investors may also be weighing potential dilution and integration risk until the deal closes, which is expected in Q4 2026. Article Title
• Negative Sentiment: Some commentary suggests the market may be cautious on the acquisition price and deal structure, with one analyst note on BioLife saying the transaction caps upside, reflecting some skepticism around valuation and near-term execution. Article Title

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on RGEN shares. Barclays lifted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Wolfe Research started coverage on shares of Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. Finally, Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $165.36.

Repligen Price Performance

The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock’s fifty day moving average price is $130.41 and its 200-day moving average price is $132.79. The firm has a market cap of $7.90 billion, a PE ratio of 155.66, a P/E/G ratio of 2.64 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same period in the prior year, the business posted $0.39 earnings per share. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities analysts forecast that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of large investors have recently added to or reduced their stakes in the business. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen in the third quarter valued at approximately $368,387,000. Opti Capital Management LP purchased a new stake in Repligen in the 4th quarter valued at approximately $2,399,209,000. Maverick Capital Ltd. acquired a new stake in Repligen during the 1st quarter valued at $178,946,000. Wasatch Advisors LP purchased a new position in Repligen during the first quarter worth $146,513,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Repligen in the fourth quarter worth $199,176,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.